Cargando…

PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA

PIK3CA mutation is considered a good candidate for targeted therapies in cancers, especially biliary tract cancer (BTC). We evaluated the utility of cell free DNA (cfDNA) from serum by using droplet digital PCR (ddPCR) as an alternative source for PIK3CA mutation analysis. To identify matching archi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seung Tae, Lira, Maruja, Deng, Shibing, Lee, Sujin, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Mao, Mao, Heo, Jin Seok, Kwon, Wooil, Jang, Kee-Taek, Lee, Jeeyun, Park, Joon Oh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741877/ https://www.ncbi.nlm.nih.gov/pubmed/26498688

Ejemplares similares

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
por: Jung, Ki Sun, et al.
Publicado: (2017)

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
por: Kim, Ju Sun, et al.
Publicado: (2017)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

PIK3CA Mutations in Hepatocellular Carcinoma in Korea
por: Kim, Heesue, et al.
Publicado: (2013)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
por: Lim, Sung Won, et al.
Publicado: (2018)

Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing()
por: Yoo, Kwai Han, et al.
Publicado: (2016)

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
por: Kim, Seung Tae, et al.
Publicado: (2016)

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
por: Lee, Su Jin, et al.
Publicado: (2018)

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
por: Kim, Seung Tae, et al.
Publicado: (2016)

Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer
por: Park, Jieun, et al.
Publicado: (2023)

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2017)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients
por: Lee, Ji Yun, et al.
Publicado: (2017)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
por: Kim, Joo Hoon, et al.
Publicado: (2016)

Mutation of the PIK3CA oncogene in human cancers
por: Karakas, B, et al.
Publicado: (2006)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Detailed analysis of phenotypes and genotypes in megalencephaly-capillary malformation-polymicrogyria syndrome caused by somatic mosaicism of PIK3CA mutations
por: Park, Hyun Jin, et al.
Publicado: (2020)

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
por: Kim, Seung Tae, et al.
Publicado: (2015)

Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer
por: Park, Hyung Soon, et al.
Publicado: (2017)

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer
por: Kodahl, Annette R., et al.
Publicado: (2018)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs
por: Kim, Hee Kyung, et al.
Publicado: (2017)

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
por: Lim, Taekyu, et al.
Publicado: (2011)

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Moonjin, et al.
Publicado: (2016)

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
por: Kim, Jinchul, et al.
Publicado: (2021)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling
por: Park, Silvia, et al.
Publicado: (2014)

Isolated Biliary Granulocytic Sarcoma Followed by Acute Myelogeneous Leukemia with Multilineage Dysplasia: A Case Report and Literature Review
por: Sung, Chang Ohk, et al.
Publicado: (2006)

Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
por: Wilhoit, Tori, et al.
Publicado: (2020)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

Development of a Swine Benign Biliary Stricture Model Using Endoscopic Biliary Radiofrequency Ablation
por: Park, Jin-Seok, et al.
Publicado: (2016)

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
por: Kim, Youjin, et al.
Publicado: (2019)

Mutations of PIK3CA in gastric adenocarcinoma
por: Li, Vivian Sze Wing, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_pnbku3f9226j26fafauqh3p5ie